Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand
July 09, 2019 01:00 ET
|
Kuros Biosciences
Kuros expands distribution of MagnetOs to Australia and New ZealandFirst sale of MagnetOs in Australia expected in 2020 SCHLIEREN (ZURICH), Switzerland, July 09, 2019 (GLOBE NEWSWIRE) -- Kuros...
Kuros Biosciences to Propose Re-Appointment of Chairman and Board Members at Annual General Meeting
April 30, 2019 01:00 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, April 30, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) will propose the re-appointment of Clemens van Blitterswijk as Chairman of the Board of Directors,...
Kuros Biosciences Reports Results for the Full Year 2018
April 12, 2019 14:00 ET
|
Kuros Biosciences
Financial highlights CHF 19.0 million cash & cash equivalents, trade and other receivables as at December 31, 2018Net operating costs decreased to CHF 14.3 million Operational highlights First...
Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million
April 09, 2019 01:00 ET
|
Kuros Biosciences
Agreement with Nice & Green S.A. can be extended for an additional CHF 5 million Provides additional funds for roll-out of MagnetOs and further advancing clinical programThe Convertible Bonds are...
Kuros Biosciences Receives US Marketing Clearance for Intervertebral Body Fusion Device
March 13, 2019 02:00 ET
|
Kuros Biosciences
510(k) clearance of the TLIF cage is an important step towards progression of Fibrin-PTH product candidate KUR-113 into clinical developmentKuro’s TLIF cage will be used in combination with its...
Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuros’s Advanced Submicron Surface Technology
February 11, 2019 01:00 ET
|
Kuros Biosciences
Global partner to market an advanced bone graft supplied by KurosAgreement demonstrates interest of major orthobiologic companies in Kuros technologies SCHLIEREN (ZURICH), Switzerland, Feb. 11,...
Kuros Ends Transformational Year With First MagnetOs Sales, Lead Clinical Program on Track, and Successful Capital Raise
December 17, 2018 01:00 ET
|
Kuros Biosciences
Successfully raised CHF 16.1 million from existing and new investorsFunding secured for fibrin-PTH Phase II in spinal fusion, a huge commercial opportunityFirst sales of MagnetOs in US and Europe,...
Kuros Announces Final Result of Capital Increase – Total Gross Proceeds of 16.1 Million Raised
December 13, 2018 15:30 ET
|
Kuros Biosciences
Not for release, publication or distribution in the USA, the United Kingdom, Canada, Japan, Australia or Member States of the European Economic Area ("EEA") SCHLIEREN (ZURICH), Switzerland, Dec. 13,...
Kuros Announces Results of Rights Offering – Capital Increase Will be Implemented
December 12, 2018 13:10 ET
|
Kuros Biosciences
Not for release, publication or distribution in the USA, the United Kingdom, Canada, Japan, Australia or Member States of the European Economic Area ("EEA") SCHLIEREN (ZURICH), Switzerland, Dec. 12,...
Kuros Receives FDA 510(k) Clearance for Extending Commercial Indications of MagnetOs Putty in the United States
December 10, 2018 01:00 ET
|
Kuros Biosciences
US Food and Drug Administration (FDA) clearance granted for extending the use of MagnetOs Putty as a stand-alone bone graft in extremities and pelvisPaves way for commercial expansion into more...